What does your board need to know about the pharmaceutical landscape in China?

Wednesday, November 13, 2024

The pharmaceutical market in China continues to show significant growth, while China-based research and development operations provide a globally important technology ecosystem. This landscape, combined with shifting geopolitical tensions and changing regulations, has created new challenges for pharmaceutical companies.

Former Senator Richard Burr, Lisa LeCointe-Cephas, Ting Xiao, Peng Tao, and Vanessa J.Le spoke on the latest developments in Chinese innovation and drug development, regulatory reform, market access, and investigations.

Our speakers discussed:

• Chinese government incentives for foreign companies entering the market and the implications of Chinese innovations entering the global marketplace
• The most important go-to-market regulatory considerations for companies developing a growth strategy in China
• The view of China from Washington, DC and vice versa, and the ramifications of the 2024 elections
• Legislative update on the BIOSECURE Act where US-China tensions have resulted in legislation looking to ban Chinese biotech companies, and
• The latest news in investigations related to Chinese pharmaceutical producers and China’s healthcare anti-corruption campaign. 

To learn more about how the result of the election could impact your business, please visit our 2024 US Presidential Election Topic Hub for timely insights, including client alerts, articles, podcasts, videos, and webinar invitations.

CLE credit was offered for this event.

For more information
Please contact Shannon Tomassi.